Rebamipide

Generic Name
Rebamipide
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H15ClN2O4
CAS Number
90098-04-7
Unique Ingredient Identifier
LR583V32ZR
Background

Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.

Indication

主要用于胃溃疡，但不宜单独用于Hp感染。也用于改善胃炎及慢性胃炎急性加重期的胃黏膜病变（如糜烂、出血、充血、水肿等）。

Associated Conditions
Gastric Ulcer
Associated Therapies
-
Clinical Trials
Related News

Rebamipide AND Sjögren Syndrome

First Posted Date
2013-01-02
Last Posted Date
2020-03-31
Lead Sponsor
University of Alexandria
Target Recruit Count
55
Registration Number
NCT01759108
Locations
🇪🇬

Faculty of Medicine, University of Alexandria, Alexandria, Egypt

The Pharmacokinetic Interaction Between Celecoxib and Rebamipide

First Posted Date
2012-03-09
Last Posted Date
2018-08-17
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
30
Registration Number
NCT01549743
Locations
🇰🇷

The Korea Univertisy Anam Hospital, Seoul, Korea, Republic of

Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?

Not Applicable
Completed
Conditions
Stomach Ulcer
Interventions
Drug: pantoprazole
Drug: Rebamipide
First Posted Date
2010-07-22
Last Posted Date
2015-09-04
Lead Sponsor
Kangdong Sacred Heart Hospital
Target Recruit Count
290
Registration Number
NCT01167101
Locations
🇰🇷

Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of

Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis

Phase 3
Completed
Conditions
Dyspepsia
Chronic Gastritis
Interventions
Drug: Rebamipide
First Posted Date
2009-10-16
Last Posted Date
2013-05-15
Lead Sponsor
PT Otsuka Indonesia
Target Recruit Count
55
Registration Number
NCT00996788
Locations
🇮🇩

Division of Gastroenterology Department of Internal Medicine - Cipto Mangunkusumo Hospital, Faculty of Medicine University of Indonesia, Jakarta, Indonesia

The Effect of Rebamipide for Non-steroidal Anti-inflammatory Drugs (NSAID) - Induced Small-intestinal Injuries

First Posted Date
2009-03-17
Last Posted Date
2009-09-21
Lead Sponsor
Nagoya University
Target Recruit Count
60
Registration Number
NCT00862628
Locations
🇯🇵

Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan

PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity

First Posted Date
2007-12-19
Last Posted Date
2011-11-16
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
396
Registration Number
NCT00576706

An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis

Phase 2
Completed
Conditions
Colitis, Ulcerative
Interventions
Drug: rebamipide
First Posted Date
2007-04-20
Last Posted Date
2021-07-20
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
124
Registration Number
NCT00463151

Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy

Phase 4
Completed
Conditions
Stomach Ulcer
Interventions
Drug: Omeprazole
Drug: Rebamipide
First Posted Date
2006-01-06
Last Posted Date
2015-04-29
Lead Sponsor
Korea Otsuka International Asia Arab
Target Recruit Count
132
Registration Number
NCT00272467
Locations
🇰🇷

Korea University Ansan Hospital, Ansan, Korea, Republic of

🇰🇷

Severance Hospital, Seoul National University, Seoul, Korea, Republic of

🇨🇳

The 1st Affiliated hospital - Zhongshan Univ., Guangzhou, Guangdong, China

and more 4 locations

Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome

Phase 2
Completed
Conditions
Xerostomia
Sjogren's Syndrome
First Posted Date
2005-10-05
Last Posted Date
2021-06-04
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
104
Registration Number
NCT00233363
Locations
🇯🇵

Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan

Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer

Phase 4
Completed
Conditions
Stomach Ulcer
First Posted Date
2005-10-05
Last Posted Date
2021-06-04
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
301
Registration Number
NCT00233389
Locations
🇯🇵

Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy